Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA) from a hold rating to a buy rating in a report released on Sunday morning.

Several other brokerages also recently issued reports on ZVRA. Cantor Fitzgerald increased their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Thursday, July 10th. HC Wainwright initiated coverage on shares of Zevra Therapeutics in a research report on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 target price on the stock. JMP Securities cut their price target on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Zevra Therapeutics in a report on Saturday, September 27th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Zevra Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Zevra Therapeutics Stock Up 1.8%

NASDAQ:ZVRA opened at $11.01 on Friday. The stock’s fifty day moving average price is $9.40 and its two-hundred day moving average price is $9.09. Zevra Therapeutics has a 52-week low of $6.19 and a 52-week high of $13.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. The company has a market cap of $617.99 million, a price-to-earnings ratio of -52.43 and a beta of 1.49.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($1.49). The firm had revenue of $25.88 million during the quarter, compared to the consensus estimate of $22.49 million. Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. On average, analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current year.

Insider Activity

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 19,500 shares of the company’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the sale, the chief executive officer owned 222,016 shares in the company, valued at approximately $2,402,213.12. This represents a 8.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John B. Bode bought 5,000 shares of the company’s stock in a transaction dated Tuesday, August 19th. The stock was purchased at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the purchase, the director owned 45,000 shares of the company’s stock, valued at approximately $412,200. This represents a 12.50% increase in their position. The disclosure for this purchase can be found here. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. increased its position in Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after purchasing an additional 1,280 shares during the period. The Manufacturers Life Insurance Company increased its position in Zevra Therapeutics by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock valued at $179,000 after purchasing an additional 1,750 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares during the period. Carret Asset Management LLC grew its position in shares of Zevra Therapeutics by 9.7% in the 2nd quarter. Carret Asset Management LLC now owns 39,640 shares of the company’s stock worth $349,000 after buying an additional 3,500 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Zevra Therapeutics by 2.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock worth $1,148,000 after buying an additional 3,827 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.